Evidence map›Paper›PMID 42035704›Full record

ArticleBrain pathology (Zurich, Switzerland)2026

Data-driven thresholds for standardized classification of severe Alzheimer's disease neuropathology using digital neuropathology.

Ryan K Shahidehpour, Allison M Neltner, Mitchell A Klusty, Cole Corbett, Angelique D Gonzalez, David A Gutman, David W Fardo, Adam D Bachstetter, Cody Bumgardner, Margaret E Flanagan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ryan K ShahidehpourSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
Allison M NeltnerSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
Mitchell A KlustyInstitute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA.
Cole CorbettGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Angelique D GonzalezGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
David A GutmanDepartment of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
David W FardoSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
Adam D BachstetterSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.ORCID https://orcid.org/0000-0003-4646-6757
Cody BumgardnerDepartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky, USA.ORCID https://orcid.org/0000-0001-9588-3501
Margaret E FlanaganGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Peter T NelsonSanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.ORCID https://orcid.org/0000-0002-6161-1265

Funding

University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
Federated digital pathology platform for AD/ADRD research and diagnosticsU24NS133945 · NINDS · UNIVERSITY OF KENTUCKY · PI BUMGARDNER, CODY, FLANAGAN, MARGARET E · 2023 to 2025
$4.9M
Brain Digital Slide Archive: An Open Source Platform for data sharing and analysis of digital neuropathologyU24NS133949 · NINDS · EMORY UNIVERSITY · PI Lee Cooper, Brittany Nicole Dugger · 2023 to 2026
$4.3M
Multi-Modal MRI to Assess Alzheimer's Disease Prevention in an APOE4 MouseModelR01AG054459 · NIA · UNIVERSITY OF MISSOURI-COLUMBIA · PI LIN, AI-LING · 2017 to 2021
$3.0M
Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)T32AG078110 · NIA · UNIVERSITY OF KENTUCKY · PI Michael Paul Murphy, LINDA J VAN ELDIK · 2022 to 2026
$2.3M
Aperio ScanScope XT Digital Slide Scanner SystemS10RR026489 · NCRR · UNIVERSITY OF KENTUCKY · PI NELSON, PETER T. · 2011 to 2011
$284k
NCRR NIH HHS S10 RR026489NIA NIH HHS P30 AG072946NIH HHS P30 AG072946NIH HHS R01 AG054459NIH HHS T32 AG078110NIH HHS U24 NS133945NIH HHS U24 NS133949
6 · The paper itself

Abstract

Alzheimer's disease neuropathological changes (ADNC)-operationalized with semi-quantitative parameters-represent the consensus-based gold standard for diagnostic evaluation of disease severity. Although useful, ADNC diagnostic frameworks have limitations, particularly in advanced disease stages where pathological severity varies widely within a given diagnostic category. Further, some individuals lacking cognitive impairment are inappropriately categorized as having severe ADNC. In this study, quantitative pathology metrics and alternative tissue sampling schemes were integrated with data about premortem cognitive status, in order to derive clinically informed neuropathologic diagnostic thresholds. Specific goals of the current study were to generate data-driven, standardized diagnostic cut-points, with the most severe stages of ADNC having consistent implications: Braak neurofibrillary tangle (NFT) stage V cases being always impaired (MCI or demented) and Braak NFT stage VI cases being always demented. Utilizing whole-slide imaging and AI-based image analysis, object-based (NFT counts) and pixel-based (phosphorylated tau [pTau] burden) quantifications were compared across neocortical regions in three subsamples of cases from the University of Kentucky ADRC autopsy cohort (n = 329, all with clinical evaluations within 2 years of death). We also compared between HALO- and Aperio-based platform results, and between AT8 and PHF-1 pTau antibodies. Applying refined thresholds enabled reclassification of cases previously misaligned with their digitally determined appropriate status: 17% of cases were thus reclassified. The use of commercially available software, standardized classifier architectures, and interoperable analysis pipelines facilitated scalable and reproducible digital quantification. Cross-institutional validation at University of Texas San Antonio, with the same algorithms applied in both research centers, confirmed near-perfect agreement of pathology counts, underscoring shareability and the feasibility of harmonized digital workflows for collaborative research and diagnostic purposes. These findings support the integration of quantitative digital pathology into standard neuropathological protocols and provide a scalable model for future multi-site studies. Enabling comparisons of analytical platforms, pTau antibodies, and anatomical sampling strategies, an updated workflow demonstrated high reproducibility and consistent clinical-pathological correlations.

Indexed as

Alzheimer DiseaseBrainNeuropathologyAgedAged, 80 and overCognitive DysfunctionFemaleHumansImage Processing, Computer-AssistedMaleNeurofibrillary TanglesSeverity of Illness Indextau Proteinstau Proteinsartificial intelligenceHALOinter‐raterPHF1ScanScopetauopathy

Identifiers

PMID42035704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.